🇺🇸 ClinicalTrials.govClinicalTrials.gov · 试验状态变更Doubao · 实盘不做把握 8/10不做原因:风险收益比不佳
北京时间·源无时间·以抓取为准·⟳ 抓取 20:02:51·⚡ 决策 10-22 20:07:28 +4m37s·5.2 天前
赛诺菲balinatunfib克罗恩病/溃疡性结肠炎长期扩展研究LTS19689状态更新，无数据、无监管里程碑
消息本质是II期长期扩展（LTE）研究在ClinicalTrials.gov的登记/状态维护：无疗效数据、无监管节点、无商业化信息，同一研究2026年4月起已在欧盟、日本、中国登记；对赛诺菲这种超大型药企完全不具materiality，无正期望交易标的。
📄 原文ClinicalTrials.gov · 试验状态变更↗ 原文
LTS19689 is a multinational, multicenter extension study to evaluate the long-term safety, tolerability and efficacy of…
不做 赛诺菲（Sanofi）（SAN.FR）
II期长期安全性扩展研究的ClinicalTrials.gov状态更新无数据、无监管里程碑、无金额，且该研究2026年4月起已在欧/日/中登记；对约1400亿欧元市值的赛诺菲不具任何materiality，无edge，不做。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
赛诺菲balinatunfib的长期安全性扩展研究LTS19689在ClinicalTrials.gov更新状态，属II期项目的常规临床运营动作，无数据读出或监管增量；赛诺菲市值巨大，单一II期LTE状态变化不构成可交易催化，回避。
消息传播链
- 节点
主要风险
- balinatunfib尚处II期阶段，长期安全性扩展研究本身不产生注册级疗效证据，母研究SPECIFI-CD/UC结果才是关键变量。
反向证据
- 做多前查反向 · 来源 web · 影响 invalidates
未发现与本状态更新同时披露的疗效顶线数据或监管批准；事件不包含可重定价的正面surprise。
检索:balinatunfib phase 3 data readout SPECIFI-CD SPECIFI-UC results 2026 原文 ↗
先例如何影响了这次决策
对本次决策的影响:先例空缺与事件性质共同支持AVOID，不设止盈止损。
方向:不适用：II期长期安全性扩展研究的登记/状态更新不构成可证券化的公司事件，没有设置交易数字的先例基础。
涨幅量级:无高相似先例；此类纯运营性登记更新对超大型药企历史上不产生显著股价反应。
形态:未检索到针对LTE研究登记状态变化的系统性交易模式；不据此交易。
工具执行结果 · 成功 2 · 降级 0 · 失败 0 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 1,931 ms
{"result": "search_processed_events:agent query=`balinatunfib lts19689 long-term extension crohn's ulcerative colitis | nct07222189 clinical trial status | specifi-cd dri18212 specifi-uc dri17822 balinatunfib`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 72.0/72 小时、26076 条本臂决策(完整)，返回 0 条候选。未命中只表示这些 agent query 表达式没有召回候 - web_search 成功 doubao_search · 1,691 ms
豆包搜索结果（原始查询:balinatunfib DRI18212 developer sponsor Dren Bio Crohn's disease；API SearchType:web）
原文全文
展开原文 · 1,643 字
LTS19689 is a multinational, multicenter extension study to evaluate the long-term safety, tolerability and efficacy of balinatunfib in participants with Crohn's disease (CD) or ulcerative colitis (UC) who completed the 52-week treatment period (on balinatunfib or placebo) in the parent studies, SPECIFI-CD (DRI18212) or SPECIFI-UC (DRI17822), respectively.
* The primary objective of this study is to assess the long-term safety and tolerability of different doses of balinatunfib in participants with CD or UC, as measured by the number and percentage of participants with CD or UC with treatment emergent adverse events (TEAEs), serious adverse events (SAEs) and adverse events of special interest (AESIs) during the study period.
* The study will consist of 2 independent cohorts through the study given the distinct nature of each disease:
* CD Cohort: comprised of CD participants enrolled from SPECIFI-CD (DRI18212).
* UC Cohort: comprised of UC participants enrolled from SPECIFI-UC (DRI17822).
* The study will consist of the following study periods for each cohort:
* A Double-Blind (DB) treatment period of up to 104 weeks for eligible participants from the DB maintenance phases of the respective parent studies.
* An Open-Label (OL) treatment period of up to 104 weeks for:
* Eligible participants from either the DB or OL periods of the parent studies,
* Eligible participants who meet escape criteria at any time during the DB period of the LTS19689.
* A 2-week follow-up period following the End of Treatment (EOT). The study duration will be up to 107 weeks, with the treatment duration up to 104 weeks.
* The primary objective of this study is to assess the long-term safety and tolerability of different doses of balinatunfib in participants with CD or UC, as measured by the number and percentage of participants with CD or UC with treatment emergent adverse events (TEAEs), serious adverse events (SAEs) and adverse events of special interest (AESIs) during the study period.
* The study will consist of 2 independent cohorts through the study given the distinct nature of each disease:
* CD Cohort: comprised of CD participants enrolled from SPECIFI-CD (DRI18212).
* UC Cohort: comprised of UC participants enrolled from SPECIFI-UC (DRI17822).
* The study will consist of the following study periods for each cohort:
* A Double-Blind (DB) treatment period of up to 104 weeks for eligible participants from the DB maintenance phases of the respective parent studies.
* An Open-Label (OL) treatment period of up to 104 weeks for:
* Eligible participants from either the DB or OL periods of the parent studies,
* Eligible participants who meet escape criteria at any time during the DB period of the LTS19689.
* A 2-week follow-up period following the End of Treatment (EOT). The study duration will be up to 107 weeks, with the treatment duration up to 104 weeks.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
ecf8786d7a· 2026-10-22 20:07 · doubao / doubao-seed-evolving-latest-version · 策略包658c0c1e2ba5当前